Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters

Clinical Medicine Insights: Cardiology

Volumn 5, Issue , 2011, Pages 85-101

  Vosper, Helen ^a  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; DP1 receptor; Extended release niacin; Flushing; Laropiprant

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; ARACHIDONIC ACID; ATORVASTATIN; DP1 RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIASPAN R; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRAVASTATIN; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOTENSION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SYNCOPE;

EID: 80053906798     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S7601     Document Type: Review

References (130)

1. Campos H, Genest JJ Jr, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-95.
2. Nesto RW. Beyond low density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379-87.
3. Despres J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl. 2006;Suppl 8: B4-12.
4. Yiu K-H, Cheung, BMY, Tse H-F. A new paradigm for managing dyslipidemia with combination therapy. Expert Opin Investig Drugs. 2010;19(3): 437-49.
5. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008;153:S68-75.
6. American Diabetes Association. Standards of medical care in diabetes. Diab Care. 2009;32:S13-61.
7. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag. 2009;5:901-8.
8. Nordestgaard BG, Chapman J, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31(23):2844-53.
9. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol. 2009;49:416-22.
10. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol. 2009;158:429-41.
11. TM). Clin Med Rev. 2011;3:1-18.
12. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98:812-5.
13. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid induced flushing. J Clin Invest. 2005;115:3634-40.
14. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126:2637-46.
15. Papaliodis D, Boucher W, Kemperaj D, et al. Niacin-induced 'flush' involves release of PGD2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther. 2008; 327:665-72.
16. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of the nicotinic acid receptor. Biophys Res Commun. 2003;303:364-9.
17. Wise A, Ford JM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278:9869-74.
18. Pike NB, Wise A. Identification of a nicotinic acid receptor: us this the molecular target for the oldest lipid-lowering drug? Curr Opin Investig Drugs. 2004;5:271-5.
19. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol. 2005;68:1271-80.
20. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother. 2010;11(10):1715-26.
21. The coronary drug project research group. The coronary drug project. Design, methods and baseline results. Circulation. 1973;47(Suppl I):I1-50.
22. The Coronary Drug project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
23. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycaemic status in patients with healed myocardial infarction (from the coronary drug project). Am J Cardiol. 2005;95:254-7.
24. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am J Cardiol. 2006;97:477-9.
25. Brown BG. Niaspan-R™ in the management of dyslipidaemia: the evidence. Eur Heart J Suppl. 2006;8(Suppl F):F60-7.
26. Brown BG, Zambon A, Poulin D, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol. 1998;81(4A): 52B-9.
27. Davidson MH. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003;5:418-22.
28. Taylor AJ, Sullenberger LE, Lee HJ, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-7.
29. Lee JM, Choudhury RP. ARBITER 2: Targeting HDL to retard atherosclerosis progession: Arterial Biology for the Investigation of Treatment Effects of Reducing cholesterol (ARBITER) 2. Br J Diabetes Vasc Dis. 2005;5: 78-80.
30. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycaemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag. 2007;3:159-64.
31. Reasner C. Niaspan-R™: a powerful treatment option for 'diabetic dyslipidaemia'. Eur Heart J Suppl. 2005;7(Suppl F):F48-55.
32. Brown BG. Niaspan-R™ in the management of dyslipidaemia: the evidence. Eur Heart J Suppl. 2006;8(Suppl F):F60-7.
33. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22(11):2243-50.
34. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J cardiol. 2008;101(10):1428-36.
35. Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. Apr 2, 2008;(2):79-90.
36. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia. Am J Cardiovasc Drug. 2008;8(2):69-81.
37. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667-72.
38. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size than atorvastatin and simvastatin. Prev Cardiol. 2003;6:179-88.
39. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-65.
40. Ferrieres J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardivasc Drugs. 2009;9(2):109-15.
41. Newby AC. An overview of the vascular response to injury: a tribute to the late Russell Ross. Toxicol Lett. 2000;112-3:519-29.
42. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med. 2001;7: 41-7.
43. Takahashi M, Masuyama J, Ikeda U, et al. Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res. 1995;76:750-7.
44. Martin-Ventura JL, Madrigal-Matute J, Munoz-Garcia B, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovasc Res. 2009;83:586-94.
45. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-81.
46. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37:1923-32.
47. Badimon L, Vilahur G, Sanchez S, Duran X. Atherosclerosis plaque formation and thrombogenesis: formation, risk factors and therapeutic approaches. Eur Heart J. 2001;3:I16-22.
48. Yoshida H, Quehenberger O, Kondratenko N, Green J, Steinberg D. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 1998;18(5):799-802.
49. Nicholson AC. Expression of CD36 in macrophages and atherosclerosis. The role of lipid regulation of PPARγ signaling. Trends Cardiovasc Med. 2004;14:8-12.
50. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004;67:411-9.
51. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-71.
52. Cipollone F, Fazia M, Iezzi A, et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol. 2004;24:1259-65.
53. Zhang J, Ge H, Wang CQ, et al. Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells. Int J Cardiol. 2007;117: 373-80.
54. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract. 2009;63(1):151-9.
55. Gadegbeku CA, Dhandauthapani A, Shrayyef MZ, et al. Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. Am J Hypertens. 2003;16:67-71.
56. Kelly JJ, Lawson JA, Campbell LV, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000; 14:567-72.
57. National Institutes of Health. NIH stops clinical trial on combination cholesterol treatment (Press release). May 26th 2011.
58. HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL-cholesterol with niacin and MK-0524. ClinicalTrials.gov Identifier: NCT00461630.
59. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid-induced insulin resistance is related to increasing circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism. 2003;52:699-704.
60. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in non-diabetic patients genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;E1775-81.
61. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002;162:1568-76.
62. McGovern M. Niaspan-R™: creating a new concept for raising HDL cholesterol. Eur Heart J Suppl. 2005;7(Suppl F):F41-7.
63. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiology. 1998;81:805-7.
64. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697-705.
65. Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther. 2008;324:883-93.
66. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis. 2007;192(2):253-8.
67. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acidand monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010; 120(8):2910-9.
68. Hussein AA, Nicholls SJ. Critical appraisal of laropiprant and extendedrelease niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Therapeut Clin Risk Manag. 2010;6: 183-90.
69. Lin W-W, Chen BC. Distinct PKC isoforms mediate the activation of cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages. Br J Pharmacol. 1998;125:1601-9.
70. Knowles HJ, Poole RT, Workman P, Harris AL. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol. 2006;71:646-56.
71. Tang Y, Zhou L, Gunnet JW, et al. Enhancement of arachidonic acid signalling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun. 2006;345:29-37.
72. 12-14PGJ2. PNAS. 2007;104(52):20979-84.
73. Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100-9.
74. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nature Rev Drug Disc. 2007;6:313-25.
75. Dunbar RL, Gelfand JM. Seeing red: flushing out instigators of niacin associated skin toxicity. J Clin Investig. 2010;120(8):2651-55.
76. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid-and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Investig. 2010;120(8):2910-9.
77. Thura M, Hokamura K, Yamamoto S, et al. GIF-0173 protects against cerebral infarction through DP1 receptor activation. Exp Neurol. 2009;219:481-91.
78. Lai E, Schwartz JI, Dallob A, et al. Effects of extended release niacin/ laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 2010;21(3):191-8.
79. Hammad H, Kool M, Soullie T, et al. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med. 2007;204(2):357-67.
80. Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009;124:942-8.
81. Mukherjee D, Topol EJ. Cyclooxygenase-2: Where are we in 2003? Cardiovascular risk and COX-2 inhibitors. Arthritis Res Therapy. 2003;5:8-11.
82. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk. JAMA. 2006;296(13):1653-6.
83. Funk C, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50(5):470-9.
84. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Investig Med. 2009;57(6):703-8.
85. Angeli V, Staumont D, Charbonnier A-S, et al. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J Immunol. 2004;172:3822-9.
86. Ahmad AS, Ahmad M, Maruyama T, Narumiya S, Dore S. Prostglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute excitotoxicity in young and old mice. Age. 2010;32:271-82.
87. Huang Z-H, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol. 2007;7:33-8.
88. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science. 2000;287:2013-7.
89. Brugger N, Kim NN, Araldi GL, Traish AM, Palmer SS. Pharmacological and functional characterization of novel EP and DP receptor agonists: DP1 receptor mediates penile erection in multiple species. J Sex Med. 2008;5(2): 344-56.
90. Fujitani Y, Aritake K, Kanaoka Y, et al. Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo. FEBS J. 2010;2277:1410-9.
91. Leblanc Y, Roy P, Dufresne C, et al. Discovery of potent and selective DP1 receptor antagonists. Bioorganic Med Chem Letts. 2009;19:2125-8.
92. Schwartz, JI, Stroh M, Gao B, et al. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Therapeut. 2009;27:239-45.
93. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010;64(6):727-38.
94. C]MK-0524, a prostaglandin D2 receptor antagonist, in humans. DMD. 35:1196-202.
95. Merck. Merck receives not approvable letter from FDA for MK-0524A (ER niacin/laropiprant). Press release issued April 28, 2008. Whitehouse Station, NJ: Merck & Co, Inc.
96. Home PD, Pocock SJ, Beck-Neilsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD): Study design and protocol. Diabetologia. 2005;48(9):1726-35.
97. Psaty BM, Furberg CD. The record on rosiglitazone and myocardial infarction. NEJM. 2007;357(1):67-9.
98. Home PD, Pocock SJ, Beck-Neilsen H, et al. Rosiglitazone evaluated for cardiac outcomes in combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009;373(9681): 2125-35.
99. Maccubbin D, Bays HE, Olsson AG, et al. Lipd-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959-70.
100. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625-30.
101. Gliem G, Liu N, Thompson-Bell S, et al. Lipid-altering efficacy and safety profile of a co-administered extended release niacin/laropiprant and simvastatin in patients with dyslipidemia. Circulation. 2007;116:II-127 (abstract 683).
102. Lang CC. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: Under scrutiny following the ENHANCE study. Cardiovasc Ther. 2008;26(2):85-8.
103. Bots ML, Baldassarre D, Alain S, et al. Carotid intima-media thickness and coronary atherosclerosis: Weak or strong relation? Eur Heart J. 2007;28:398-496.
104. Kastelein JJ,Adkim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-43.
105. Bays HE, Maccubbin D, Meehan AG. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post-hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther. 2009;31(1):115-2.
106. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/ laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. 2009;114:192-8.
107. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extendedrelease niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
108. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009;63(9):1369-77.
109. Sood A, Arora R. Mechanism of flushing due to niacin and the abolition of these effects. J Clin Hypertens. 2009;11(11):685-9.
110. Thakkar RB, Kashyap ML, Lewin AJ, et al. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(2):69-79.
111. European Medicines Agency. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrythmic drugs: E14, Geneva, Switzerland. 2005.
112. Luo WL, Crumley T, Ebel D, et al. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers. J Clin Pharmacol. 2010;50:1273-9.
113. Davis TME, Millns SH, Stratton IM, Holman RR, Turner RC. Risk factors of stroke in Type 2 diabetes mellitus. United Kingdom Prospective {Eth}iabetes Study (UKPDS) 29. Arch Intern Med. 1999;159:1097-103.
114. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-51.
115. Schwartz JI, Liu F, Stroh M, et al. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther. 2009;16(3):215-23.
116. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol. 1998; 82:74U-86.
117. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697-705.
118. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E, on behalf of the NAUTILUS Study Group. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Current Med Res Opin. 2006;22:417-25.
119. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. NAUTILUS (safety and tolerability of Niaspan-R™): a subgroup analysis in patients with diabetes. Diabetes Vasc Dis. 2006;6(3):127-33.
120. Parra JL, Ruddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7(2):415-33.
121. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329(2):62-5.
122. Navarro VS, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-9
123. Chang CY, Schiano TD. Drug hepatotoxicity. Alimentary Pharmacol Ther. 2007;25(10):1135-51.
124. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on statins. Circulation. 2002;106:1024-8.
125. Bellosta S, Paoletti R, Corsini A. Atherosclerosis: Evolving vascular biology and clinical implications. Circulation. 2004;109:III-50-7.
126. Smorgorzewski M. The myopathy of statins. J Renal Nutr. 2005;15(1): 87-93.
127. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low/HDL/ high triglycerides: Impact on Global health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538-43.
128. Abbott Press release: Statement on interim study results of AIM-HIGH. Available at: http://www.abbott.com/PressRelease/2011May26.htm. (last accessed 23/08/11.
129. Dolgin E. Trial puts niacin-and cholesterol dogma-in the line of fire. Nature Med. 17:756.
130. Available at: http://www.cardioexchange.org/voices/aim-high-halted-adeath-knell-for-the-hdl-hypothesis/. (last accessed 21/07/11). doi: 10.4137/CMC.S7601.